LORBRENA

The Lorbrena Product Monograph is available here.

LORBRENA (lorlatinib) is indicated as:

• monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
• monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib.
  The marketing authorization for the second and later line indication was based on a primary efficacy endpoint of tumor objective response rate and duration of response; no overall survival benefit has been demonstrated.